BrYet gets AIFA approval for cGMP line for ML-016
BrYet announced AIFA approval of a first-in-kind cGMP manufacturing line for ML-016, supporting imminent clinical supply to Australia.
HOUSTON, TX / / September 9, 2026 / BrYet US, Inc. ("BrYet") said AIFA has approved a first-in-kind cGMP manufacturing line for ML-016, the company's lead clinical-stage program for advanced cancers.